Dogwood Therapeutics’ (DWTX) “Buy” Rating Reiterated at HC Wainwright

Dogwood Therapeutics (NASDAQ:DWTX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Separately, Weiss Ratings downgraded Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dogwood Therapeutics has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Trading Down 7.1%

NASDAQ DWTX opened at $1.70 on Tuesday. Dogwood Therapeutics has a 1-year low of $1.28 and a 1-year high of $9.50. The company has a 50 day moving average of $2.07 and a 200-day moving average of $3.59. The firm has a market cap of $56.78 million, a price-to-earnings ratio of -0.16 and a beta of 1.68.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. On average, analysts forecast that Dogwood Therapeutics will post -0.93 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.